What is DreaMed Diabetes?
Founded in 2014, DreaMed Diabetes operates at the intersection of medical device engineering and digital health. The company specializes in personalized diabetes treatment optimization, most notably through its DreaMed Advisor portfolio. As a pioneer in the field, DreaMed achieved a significant regulatory milestone by securing both CE Mark and FDA clearance for its Advisor Pro system, which provides actionable decision support for Type I diabetes patients. By integrating data from continuous glucose monitors and insulin pumps, the platform empowers healthcare professionals to deliver highly personalized insulin therapy, effectively bridging the gap between complex patient data and clinical decision-making.
How much funding has DreaMed Diabetes raised?
DreaMed Diabetes has raised a total of $5.3M across 2 funding rounds:
Private Equity
$2M
Private Equity
$3.3M
Private Equity (2015): $2M with participation from Medtronic
Private Equity (2016): $3.3M, investors not publicly disclosed
Key Investors in DreaMed Diabetes
Medtronic
Medtronic is a global healthcare technology leader that develops and manufactures medical devices, therapies, and digital health solutions across a wide range of chronic conditions.
What's next for DreaMed Diabetes?
With the recent influx of capital, DreaMed Diabetes is well-positioned to accelerate the development of its broader Advisor portfolio, aiming to extend its decision support capabilities to a wider demographic of patients regardless of their specific insulin therapy or diabetes type. The strategic focus will likely center on deepening clinical integration and expanding market penetration for its existing software-as-a-medical-device solutions. As the company matures, the emphasis will shift toward long-term scalability and the establishment of new partnerships within the global healthcare ecosystem to ensure that its personalized treatment algorithms become a standard of care in chronic disease management.
See full DreaMed Diabetes company page
